Fundraising FoxJounce Therapeutics
AcquiredCambridge, US · Founded 2012 · Delaware corporation · 7 known investors
Find your way into Jounce Therapeutics
Sign up to see every warm intro you have to Jounce Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Jounce Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Concentra Biosciences, LLC March 2023 · $97.5M ($1.85 per share cash plus CVR; total deal ~$97.5M) · source ↗
Jounce Therapeutics was a Cambridge, MA clinical-stage biopharmaceutical company developing cancer immunotherapies, including antibodies targeting ICOS and LILRB2/ILT4, guided by a biomarker-driven discovery platform.
Founders & leadership
Board
Investors · 7
How we know: Boutique Venture Partners's portfolio page · Not right? Tell us
How we know: GENERAL INCEPTION's portfolio page · Not right? Tell us
How we know: Nextech Invest's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Sofinnova Ventures's portfolio page · Not right? Tell us
How we know: Venture Capital Investment Management's portfolio page · Not right? Tell us
How we know: a partner's Signal profile · board seat on SEC Form D · funding news · open dataset · 5k.vc investor directory · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$91M disclosed across 2 rounds · 2015–2020
▶$35MraisedOct 2020 · 1 investors · BiotechnologyRule 506(b)
- Luis A. Diaz, Jr.Director
- Duncan HiggonsDirector
- Robert IannoneDirector
- Robert KamenDirector
- Cary PfefferDirector
- Robert TepperDirector
- Perry KarsenDirector
- Elizabeth G. TrehuExecutive Officer
- Hugh M. ColeExecutive Officer
- Kimberlee C. DrapkinExecutive Officer
- Richard MurrayExecutive Officer, Director
- Barbara DuncanDirector
- Offering amount
- $35M
- Amount sold
- $35M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$56MraisedApr 2015 · 14 investors · BiotechnologyRule 506(b)
- Robert TepperDirector
- Kim C. DrapkinExecutive Officer
- Anna L. BarryExecutive Officer
- Richard MurrayExecutive Officer, Director
- Cary G. PfefferDirector
- Robert KamenDirector
- Offering amount
- $56M
- Amount sold
- $56M
- First sale
- Apr 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Jounce Therapeutics went on to found or lead other companies.
Frequently asked questions
- What does Jounce Therapeutics do?
- Jounce Therapeutics was a Cambridge, MA clinical-stage biopharmaceutical company developing cancer immunotherapies, including antibodies targeting ICOS and LILRB2/ILT4, guided by a biomarker-driven discovery platform.
- Who are Jounce Therapeutics's investors?
- Jounce Therapeutics's investors include Boutique Venture Partners, GENERAL INCEPTION, Nextech Invest, Sofinnova Ventures, Venture Capital Investment Management, Third Rock Ventures, Wellington Management.
- How much funding has Jounce Therapeutics raised?
- Jounce Therapeutics has disclosed $91M raised across 2 rounds.
- Where is Jounce Therapeutics headquartered?
- Jounce Therapeutics is headquartered in Cambridge, US.